The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.
Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Wuxi No. 4 People's Hospital
Wuxi, Jiangsu, China
RECRUITINGSafety data included vital signs (blood pressure, respiratory rate, heart rate, and body temperature) (composite)
Safety data were collected before and after injection of 18F-Al-NOTA-PRGD2. physical examination; ECG; laboratory parameters (blood routine, liver function and kidney function) and adverse events.
Time frame: 1 day
radioactive distribution of normal organ, standard uptake value of tumor
Visual analysis whole body 18F-Al-NOTA-PRGD2 PET;Regions of interest (ROIs) were drawn manually on each image with the assistance of corresponding CT images. The results were expressed as standardized uptake value (SUV).
Time frame: 60 minutes
Diagnostic performance analysis to assess "sensitivity,specificity,accuracy,etc"
compare the Diagnostic outcome to pathology or clinic follow-up,then to gather statistics of sensitivity,specificity,accuracy,etc.
Time frame: 1 day-1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.